DUBLIN, Ireland, Oct. 11, 2011 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the third quarter of fiscal year 2011 on Thursday, October 20, 2011. The Company has scheduled a conference call for that same day, Thursday, October 20, 2011 at 11:00am EDT (4:00pm BST) to discuss the results of the quarter.
Interested parties can access the call by dialing:
| USA: | 1-877-317-6789 |
| International: | 1-412-317-6789 |
| Conference ID #: | 10005443 |
A simultaneous webcast of the call can be accessed at: http://www.videonewswire.com/event.asp?id=82827
A replay of the call can be accessed until October 26, 2011 by dialing:
| USA: | 1-877-344-7529 |
| International: | 1-412-317-0088 |
| Conference ID #: | 10005443 |
The webcast of the call will be available for 30 days at: http://www.videonewswire.com/event.asp?id=82827
About Trinity Biotech plc
Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com.
The Trinity Biotech PLC logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10602
Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.